Cardizem LA

May 2004
Formulary;May2004, Vol. 39 Issue 5, p239
Academic Journal
Provides information on Biovail Corp.'s extended-release calcium antagonist Cardizem LA, which has been approved by the U.S. Food and Drug Administration for the treatment of chronic stable angina.


Related Articles

  • Pipeline preview.  // Formulary;Dec2005, Vol. 40 Issue 12, p425 

    The article reports on drugs recommended for approval. Thalidomide is recommended for the treatment of multiple myeloma. The U.S. Food and Drug Administration recommended a fast-track designation for vascular endothelial growth factor-2 for the treatment of severe angina associated with...

  • Ranolazine. Abrams, Jonathan; Jones, Carole A.; Kirkpatrick, Peter // Nature Reviews Drug Discovery;Jun2006, Vol. 5 Issue 6, p453 

    Ranolazine (Ranexa; Cardiovascular Therapeutics) was approved by the US FDA for the treatment of chronic angina in January 2006. It is the first drug in a new class for treating this condition to be approved in the United States in more than 20 years.

  • New Treatment for Chest Pain.  // FDA Consumer;May/Jun2006, Vol. 40 Issue 3, p2 

    The article reports on the approval of the chronic angina treatment Ranexa by the U.S. Food and Drug Administration in 2006. The drug can only be used by people who have not responded to other anti-anginal drugs because it affects electrical conduction in the heart. Nitroglycerin is used to...

  • NEW DRUGS.  // Drug Topics;1/28/2008, Vol. 152 Issue 2, special section p28 

    The article reports on the approval of the Food and Drugs Administration to the new beta blocker Bystolic medicine from Forest Laboratories. The new beta blocker Bystolic has been approved for the treatment of hypertension. It will be available in 2.5-milligram, 5-milligram, and 10-milligram...

  • Extended-Release Metformin Combo Drug Given the Green Light. Trecroci, D. // Diabetes Health;Dec2005, Vol. 14 Issue 12, p19 

    Reports on the approval of the drug Glumetza, a formulation of metformin hydrochloride manufactured by Biovail, by the U.S. Food and Drug Administration. Use of the drug for the treatment of type 2 diabetes; Potential advantages of the drug; Common side effects of the drug.

  • Biovail files NDA for pain drug Ralivia.  // PharmaWatch: Biotechnology;May 2004, Vol. 3 Issue 5, p13 

    Focuses on the submission of a new drug application to the U.S. Food and Drug Administration by Biovail Corp. for Ralivia Flashdose for the treatment of moderate to severe pain. Description of Ralivia Flashdose; Provision of choice of administration with or without water; Benefit to patients...

  • Biovail shares depressed on Wellbutrin generic filing.  // PharmaWatch: CNS;January 2005, Vol. 4 Issue 1, p10 

    Reports that Biovail Corp.'s shares have hit a one-year low after it confirmed that Anchen Pharmaceuticals company had submitted an abbreviated new drug application to the U.S. Food and Drug Administration to market a generic version of antidepressant medication Wellbutrin XL. Formulations of...

  • GlaxoSmithKline receives FDA approvable letter for Wellbutrin XL.  // PharmaWatch: CNS;August 2003, Vol. 2 Issue 8, p10 

    Reports on the approval of the antidepressant Wellbutrin XL tablets of GlaxoSmithKline PLC by the U.S. Food and Drug Administration. Increase in the treatment options for adults with depression; License agreement between the firm and Biovail Corp.; Efforts of the company to work with the agency...

  • Biovail files NDA for novel dosage form of anti-depressant.  // PharmaWatch: Biotechnology;July 2004, Vol. 3 Issue 7, p12 

    Reports on the acceptance of the U.S. Food and Drug Administration to Biovail Corp.'s submission of a new drug application for a novel dosage format of citalopram for the treatment of depression. Product offering; Characterization of citalopram hydrobomide; Market penetration of citalopram.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics